Category: Baxter International
Baxter posts a modest bump in sales and meets Wall Street's earnings expectations for its 1st quarter 2013.
Baxter (NYSE:BAX) met Wall Street's expectations with its Q1 2013 financial report, but that didn't keep the company's stock from sinking this morning.
Minnesota regulators offer a raft of tax incentives to top companies in efforts to lure them to the North Star State.
Minnesota regulators are offering tax incentives in hopes of luring more large corporations to the North Star State, and at least one major medical device and diagnostics player is thinking of taking advantage of the offer.
Baxter issues alerts about its HomeChoice peritoneal dialysis machines in Canada and Hong Kong.
Baxter (NYSE:BAX) alerted Canadian peritoneal dialysis patients about potential overfill issues with its HomeChoice machines and tipped Hong Kong regulators about the risks of altering the HomeChoice device's power cord to fit local outlets.
The top 5 medical device industry lobbying spenders doled out more than $11.5 million in political contributions in 2012.
Medical device makers reported nearly $29 million in campaign contributions in 2012, with nearly 40% of that coming from just the top 5 donors.
Medical device maker Puerto Rico will cut 400 employees from a Puerto Rico facility where it will invest $35 million for a new manufacturing line.
MASSDEVICE ON CALL — Baxter (NYSE:BAX) told reporters this week that the company is cutting 400 positions from a facility in Puerto Rico, where it is also investing $35 million for a brand new manufacturing line.
The cuts represent 44% of the facility's workforce, where Baxter last year invested $2.5 million for a small production line.
Medtronic now owns nearly 25% of Chinese medical device company LifeTech.
Medtronic (NYSE:MDT) said it's closed a $66 million investment in Chinese medical device company LifeTech Scientific (HK:8122).
Second Sight Medical registers for a $25 million funding round as it awaits the FDA's decision on its Argus II "bionic eye" retinal implant.
Second Sight Medical registered with the SEC for a $25 million offering of equity, debt, options and warrants as it waits for the FDA to decide whether to give the green light to its "bionic eye" retinal implant.
The Sylmar, Calif.-based medical device company filed with the securities watchdog agency yesterday, saying it has yet to sell any of the $1,000 shares in the offering.